Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children
Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases Jg. 74; H. 8; S. 1372 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
28.04.2022
|
| Schlagworte: | |
| ISSN: | 1537-6591, 1537-6591 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB.
Pharmacokinetic data were pooled from 2 observational studies in South African children with RR-TB routinely treated with oral moxifloxacin once daily. The population pharmacokinetics and Fridericia-corrected QT (QTcF)-interval prolongation were characterized in NONMEM. Pharmacokinetic simulations were performed to predict expected exposure and optimal weight-banded dosing.
Eighty-five children contributed pharmacokinetic data (median [range] age of 4.6 [0.8-15] years); 16 (19%) were aged <2 years, and 8 (9%) were living with human immunodeficiency virus (HIV). The median (range) moxifloxacin dose on pharmacokinetic sampling days was 11 mg/kg (6.1 to 17). Apparent clearance was 6.95 L/h for a typical 16-kg child. Stunting and HIV increased apparent clearance. Crushed or suspended tablets had faster absorption. The median (range) maximum change in QTcF after moxifloxacin administration was 16.3 (-27.7 to 61.3) ms. No child had QTcF ≥500 ms. The concentration-QTcF relationship was nonlinear, with a maximum drug effect (Emax) of 8.80 ms (interindividual variability = 9.75 ms). Clofazimine use increased Emax by 3.3-fold. Model-based simulations of moxifloxacin pharmacokinetics predicted that current dosing recommendations are too low in children.
Moxifloxacin doses above 10-15 mg/kg are likely required in young children to match adult exposures but require further safety assessment, especially when coadministered with other QT-prolonging agents. |
|---|---|
| AbstractList | Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB.
Pharmacokinetic data were pooled from 2 observational studies in South African children with RR-TB routinely treated with oral moxifloxacin once daily. The population pharmacokinetics and Fridericia-corrected QT (QTcF)-interval prolongation were characterized in NONMEM. Pharmacokinetic simulations were performed to predict expected exposure and optimal weight-banded dosing.
Eighty-five children contributed pharmacokinetic data (median [range] age of 4.6 [0.8-15] years); 16 (19%) were aged <2 years, and 8 (9%) were living with human immunodeficiency virus (HIV). The median (range) moxifloxacin dose on pharmacokinetic sampling days was 11 mg/kg (6.1 to 17). Apparent clearance was 6.95 L/h for a typical 16-kg child. Stunting and HIV increased apparent clearance. Crushed or suspended tablets had faster absorption. The median (range) maximum change in QTcF after moxifloxacin administration was 16.3 (-27.7 to 61.3) ms. No child had QTcF ≥500 ms. The concentration-QTcF relationship was nonlinear, with a maximum drug effect (Emax) of 8.80 ms (interindividual variability = 9.75 ms). Clofazimine use increased Emax by 3.3-fold. Model-based simulations of moxifloxacin pharmacokinetics predicted that current dosing recommendations are too low in children.
Moxifloxacin doses above 10-15 mg/kg are likely required in young children to match adult exposures but require further safety assessment, especially when coadministered with other QT-prolonging agents. Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB.BACKGROUNDMoxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB.Pharmacokinetic data were pooled from 2 observational studies in South African children with RR-TB routinely treated with oral moxifloxacin once daily. The population pharmacokinetics and Fridericia-corrected QT (QTcF)-interval prolongation were characterized in NONMEM. Pharmacokinetic simulations were performed to predict expected exposure and optimal weight-banded dosing.METHODSPharmacokinetic data were pooled from 2 observational studies in South African children with RR-TB routinely treated with oral moxifloxacin once daily. The population pharmacokinetics and Fridericia-corrected QT (QTcF)-interval prolongation were characterized in NONMEM. Pharmacokinetic simulations were performed to predict expected exposure and optimal weight-banded dosing.Eighty-five children contributed pharmacokinetic data (median [range] age of 4.6 [0.8-15] years); 16 (19%) were aged <2 years, and 8 (9%) were living with human immunodeficiency virus (HIV). The median (range) moxifloxacin dose on pharmacokinetic sampling days was 11 mg/kg (6.1 to 17). Apparent clearance was 6.95 L/h for a typical 16-kg child. Stunting and HIV increased apparent clearance. Crushed or suspended tablets had faster absorption. The median (range) maximum change in QTcF after moxifloxacin administration was 16.3 (-27.7 to 61.3) ms. No child had QTcF ≥500 ms. The concentration-QTcF relationship was nonlinear, with a maximum drug effect (Emax) of 8.80 ms (interindividual variability = 9.75 ms). Clofazimine use increased Emax by 3.3-fold. Model-based simulations of moxifloxacin pharmacokinetics predicted that current dosing recommendations are too low in children.RESULTSEighty-five children contributed pharmacokinetic data (median [range] age of 4.6 [0.8-15] years); 16 (19%) were aged <2 years, and 8 (9%) were living with human immunodeficiency virus (HIV). The median (range) moxifloxacin dose on pharmacokinetic sampling days was 11 mg/kg (6.1 to 17). Apparent clearance was 6.95 L/h for a typical 16-kg child. Stunting and HIV increased apparent clearance. Crushed or suspended tablets had faster absorption. The median (range) maximum change in QTcF after moxifloxacin administration was 16.3 (-27.7 to 61.3) ms. No child had QTcF ≥500 ms. The concentration-QTcF relationship was nonlinear, with a maximum drug effect (Emax) of 8.80 ms (interindividual variability = 9.75 ms). Clofazimine use increased Emax by 3.3-fold. Model-based simulations of moxifloxacin pharmacokinetics predicted that current dosing recommendations are too low in children.Moxifloxacin doses above 10-15 mg/kg are likely required in young children to match adult exposures but require further safety assessment, especially when coadministered with other QT-prolonging agents.CONCLUSIONSMoxifloxacin doses above 10-15 mg/kg are likely required in young children to match adult exposures but require further safety assessment, especially when coadministered with other QT-prolonging agents. |
| Author | Garcia-Prats, Anthony J Radtke, Kendra K Savic, Radojka M Thee, Stephanie Winckler, J L Draper, Heather R Hesseling, Anneke C Schaaf, H Simon Nielsen, James Wiesner, Lubbe van der Laan, Louvina E Solans, Belen P Fourie, Barend |
| Author_xml | – sequence: 1 givenname: Kendra K orcidid: 0000-0002-0578-6554 surname: Radtke fullname: Radtke, Kendra K organization: Department of Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, California, USA – sequence: 2 givenname: Anneke C surname: Hesseling fullname: Hesseling, Anneke C organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa – sequence: 3 givenname: J L surname: Winckler fullname: Winckler, J L organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa – sequence: 4 givenname: Heather R surname: Draper fullname: Draper, Heather R organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa – sequence: 5 givenname: Belen P surname: Solans fullname: Solans, Belen P organization: Department of Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, California, USA – sequence: 6 givenname: Stephanie surname: Thee fullname: Thee, Stephanie organization: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin , Berlin, Germany – sequence: 7 givenname: Lubbe surname: Wiesner fullname: Wiesner, Lubbe organization: Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa – sequence: 8 givenname: Louvina E surname: van der Laan fullname: van der Laan, Louvina E organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa – sequence: 9 givenname: Barend surname: Fourie fullname: Fourie, Barend organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa – sequence: 10 givenname: James surname: Nielsen fullname: Nielsen, James organization: Department of Pediatrics, New York University School of Medicine, New York, New York, USA – sequence: 11 givenname: H Simon surname: Schaaf fullname: Schaaf, H Simon organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa – sequence: 12 givenname: Radojka M surname: Savic fullname: Savic, Radojka M organization: Department of Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, California, USA – sequence: 13 givenname: Anthony J surname: Garcia-Prats fullname: Garcia-Prats, Anthony J organization: University of Wisconsin, Department of Pediatrics, Madison, Wisconsin, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34286843$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1LxDAQxYMofp-8S44erDZf3fQo6ycoyrqel2kycaNtsiYtuOAfb0EFD48ZHr95A2-PbIYYkJAjVp6xshbnxttR0FSSbZBdpsSkqFTNNv_tO2Qv57eyZEyXapvsCMl1paXYJV8P8dO7Nn6C8YE-LSF1YOK7D9h7k0_pFJL1YOgzOOzXpxSCpZcx-_BKXUy0XyKdJ4S-w9DT6OjMO-hWfgwrZph97mH050ODyQzteJfp-Ga69K1NGA7IloM24-Hv3Ccv11fz6W1x_3hzN724L4xkvC-E4hZLbiegjKj0RIPjjdZQi1orlIJZoxmXqq60qxtrjZWOS4dgEcFUhu-Tk5_cVYofA-Z-0flssG0hYBzygislNKtLJUf0-Bcdmg7tYpV8B2m9-GuMfwNix3HK |
| CitedBy_id | crossref_primary_10_1007_s00018_022_04450_8 crossref_primary_10_1097_INF_0000000000003742 crossref_primary_10_1016_j_envres_2024_120349 crossref_primary_10_1093_cid_ciae024 crossref_primary_10_1128_aac_01448_22 crossref_primary_10_5588_ijtldopen_25_0446 crossref_primary_10_1093_cid_ciac252 crossref_primary_10_3390_pathogens12111372 crossref_primary_10_1111_bcp_70005 crossref_primary_10_1016_j_ijantimicag_2022_106620 crossref_primary_10_3389_fmed_2025_1467001 crossref_primary_10_1097_MOP_0000000000001226 crossref_primary_10_1128_aac_00794_23 crossref_primary_10_1080_14787210_2023_2285917 crossref_primary_10_1016_S2352_4642_25_00025_2 crossref_primary_10_1016_j_addr_2024_115364 crossref_primary_10_58838_2075_1230_2025_103_4_24_31 crossref_primary_10_1128_aac_00441_22 crossref_primary_10_3390_pathogens11040381 crossref_primary_10_1002_bcp_70005 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/cid/ciab641 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| ExternalDocumentID | 34286843 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: UM1 AI068636 – fundername: NIAID NIH HHS grantid: UM1 AI106701 – fundername: NIAID NIH HHS grantid: UM1 AI069521 – fundername: NICHD NIH HHS grantid: R01 HD069169 – fundername: NICHD NIH HHS grantid: R01 HD083047 – fundername: NIAID NIH HHS grantid: U01 AI068632 – fundername: NIAID NIH HHS grantid: UM1 AI068632 – fundername: NIAID NIH HHS grantid: UM1 AI068634 |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 29B 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABZA AACGO AACZT AAJKP AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPLY ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN AQKUS ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMOBN ENERS ESX F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HW0 HZ~ IOX J21 JLS JSG KAQDR KOP KSI KSN L7B M49 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y RD5 ROX ROZ RUSNO RW1 RXO SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- 7X8 ABPQP ADNBA AEMQT AFYAG AHGBF AJBYB AJNCP ALXQX JXSIZ KBUDW |
| ID | FETCH-LOGICAL-c412t-352de02d7a5c36878af2b88a93985e431dc81245968f9bddcd4f24feadeeac6c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 22 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000756432400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-6591 |
| IngestDate | Sun Nov 09 14:06:27 EST 2025 Wed Feb 19 02:26:10 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | pharmacokinetics pediatrics tuberculosis moxifloxacin |
| Language | English |
| License | The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c412t-352de02d7a5c36878af2b88a93985e431dc81245968f9bddcd4f24feadeeac6c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-0578-6554 |
| OpenAccessLink | https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab641/39972936/ciab641.pdf |
| PMID | 34286843 |
| PQID | 2553819054 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2553819054 pubmed_primary_34286843 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-28 |
| PublicationDateYYYYMMDD | 2022-04-28 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-28 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical infectious diseases |
| PublicationTitleAlternate | Clin Infect Dis |
| PublicationYear | 2022 |
| SSID | ssj0011805 |
| Score | 2.4953938 |
| Snippet | Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data,... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1372 |
| SubjectTerms | Adult Child Child, Preschool Electrocardiography Fluoroquinolones - adverse effects HIV Infections Humans Moxifloxacin - adverse effects Rifampin - adverse effects Rifampin - pharmacokinetics Tuberculosis - drug therapy Tuberculosis, Multidrug-Resistant - drug therapy |
| Title | Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34286843 https://www.proquest.com/docview/2553819054 |
| Volume | 74 |
| WOSCitedRecordID | wos000756432400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qRLz4_f1BBI8G1yRt05PIdHjZGDpht5EmeTDUdtpNFPzjfekyPAmCl0JbkqbJy8vvfRNyjicixAloFkcgmcwlsCxzwPDolxHEqVCprYtNpN2uGgyyXlC4VcGtcs4Ta0ZtS-N15JcIfb1wgQjjavzKfNUob10NJTQWSUMglPFUnQ5-rAiRql0YcVOnLImzKMTnoRB_aXCp8efzREa_Y8v6jGmv_3d0G2QtoEt6PSOHTbLgii2y0gn2823y1Sk_RvBcfmi8p72QtvoJ3_lszRe0VdOLoQ8a3OTzgurC0pvSqxMogluKYJH2557ptAR6PwL9Mvads3tXeSiKz_vT3L2Z6TO2qyh-phXixXfIY_u237pjof4CMzLiE4bYzLomt6mOjUhUqjTwXCmdiUzFDpGHNR4exFmiIMutNVYCl-BdsJGdJ4bvkqWiLNw-oRaUFdwY7E1InSa5aoIwsTPcuKYV6oCczed1iPTtjRa6cOW0Gv7M7AHZmy3OcDxLxDEUKDslSorDP7Q-IqvcRy40JePqmDQAd7c7IcvmfTKq3k5rwsFrt9f5BqL_0R4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Moxifloxacin+Pharmacokinetics%2C+Cardiac+Safety%2C+and+Dosing+for+the+Treatment+of+Rifampicin-Resistant+Tuberculosis+in+Children&rft.jtitle=Clinical+infectious+diseases&rft.au=Radtke%2C+Kendra+K&rft.au=Hesseling%2C+Anneke+C&rft.au=Winckler%2C+J+L&rft.au=Draper%2C+Heather+R&rft.date=2022-04-28&rft.eissn=1537-6591&rft.volume=74&rft.issue=8&rft.spage=1372&rft_id=info:doi/10.1093%2Fcid%2Fciab641&rft_id=info%3Apmid%2F34286843&rft_id=info%3Apmid%2F34286843&rft.externalDocID=34286843 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon |